At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 11 enrolled
Drug / intervention
Ruxolitinib 1.5% Phosphate Creamdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Open Label Phase 2 Proof-of-concept Pilot Trial of Topical Ruxolitinib in Repigmenting Adult Patients With Vitiligo
In Brief
A Phase 2 clinical trial evaluating Ruxolitinib 1.5% Phosphate Cream for Vitiligo. Completed, enrolled 11 participants across 1 site.
Detailed Summary
The purpose of this study is to determine if topical ruxolitinib 1.5% will provide repigmentation in vitiligo lesions.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsVitiligo
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartJan 2016
First PostedJun 2016
Primary CompletionJan 2017
Study CompletionFeb 2017
TodayJul 2026
First PostedJun 22, 2016
Enrollment StartJan 1, 2016
Primary CompletionJan 1, 2017
Study CompletionFeb 1, 2017
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 10.0 years ago
Interventions
Ruxolitinib 1.5% Phosphate Creamdrug
twice daily topical application of Ruxolitinib 1.5% Phosphate Cream beginning at baseline and ending at week 20